Skip to main content
main-content

EULAR 2019

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Annual European Congress of Rheumatology coverage

Madrid, Spain (June 12–15). Breaking news and expert interviews on the FINCH 1 and 3, and SPIRIT-H2H trials.


Conference overview

The 2019 European Congress of Rheumatology (EULAR 2019) featured the latest research and clinical guidance in rheumatology, and encompassed a wide variety of themes, including:

Featured

Expert interviews

15-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 3 trial

Roy Fleischmann discusses his main take-home messages from the FINCH 3 trial (1:57).

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Expert commentary: The SPIRIT-H2H trial

Laura Coates discusses why the results of the SPIRIT-H2H trial are important for clinical practice (2:41).

15-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 1 trial

Roy Fleischmann gives his perspective on the FINCH 1 trial results (1:58)

15-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: The FINCH 3 trial

Rene Westhovens summarizes the results of the FINCH 3 trial, which investigated filgotinib with and without methotrexate in rheumatoid arthritis patients with no prior methotrexate exposure (3:40).

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: The SPIRIT-H2H trial

Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixekizumab versus adalimumab in patients with psoriatic arthritis (7:15).

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 1 and FINCH 3 trials

John Isaacs comments on the findings from the FINCH 1 and FINCH 3 trials and discusses how filgotinib might fit into the rheumatoid arthritis treatment landscape (2:56).

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: Fenebrutinib in RA

Roy Fleischmann gives his thoughts on the phase IIb fenebrutinib findings in patients with biologic DMARD-refractory rheumatoid arthritis (1:09).

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: The ORAL Shift trial

Stanley Cohen discusses the latest findings from the trial looking at methotrexate withdrawal in patients with rheumatoid arthritis achieving low disease activity with tofacitinib (2:11).  

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: The FINCH 1 trial

Bernard Combe takes us through the findings from the FINCH 1 trial of filgotinib in rheumatoid arthritis patients with an inadequate response to methotrexate (7:19).

12-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: Phase IIb study of fenebrutinib in RA patients

Stanley Cohen discusses the key results for the multi-dose trial of fenebrutinib versus placebo and adalimumab in patients with rheumatoid arthritis refractory to methotrexate or prior tumor necrosis inhibitor therapy (2:05).

12-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: Tildrakizumab shows promise for PsA

Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for the treatment of psoriatic arthritis (8:45).

Research news

25-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Positive secukinumab results for axial manifestations in PsA

Secukinumab improves axial manifestations in patients with psoriatic arthritis and an inadequate response to nonsteroidal anti-inflammatory drugs, primary analysis of the phase III MAXIMISE trial shows.

25-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Ixekizumab efficacious in PsA following one or two inadequate anti-TNF responses

Patients with psoriatic arthritis who have an inadequate response to one or two tumor necrosis factor inhibitors may benefit from ixekizumab, suggests research presented at the EULAR 2019 congress in Madrid, Spain.

21-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Ultra-low rituximab doses may not be appropriate in RA

A randomized trial has failed to demonstrate noninferiority of ultra-low dose rituximab to a standard low dose of the drug in patients with rheumatoid arthritis.

EULAR 2019 pre-conference content

Key clinical trials at EULAR 2019

Get up to speed on the clinical trials headlining EULAR 2019 with our brief overviews.

Session recommendations

EULAR President Hans Bijlsma shares his recommended sessions ahead of EULAR 2019.

Image Credits